J&J enters deal with Second Genome to study gut bacteria

Johnson & Johnson partnered with a startup company to study gut bacteria in hopes of developing drugs for bowel disease.

Johnson & Johnson partnered with a startup company to study gut bacteria in hopes of developing drugs for bowel disease.

Terms of the deal between J&J’s Janssen Biotech and Second Genome weren’t disclosed. San Bruno, California-based Second Genome concentrates on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category